Aminoglycoside nephrotoxicity: do time and frequency of administration matter?
Aminoglycosides remains the mainstay in the treatment of gram-negative infections despite their potential oto-and nephrotoxicity although alternatives with equal or better efficacy are available. Several approaches were investigated to decrease aminoglycosides nephrotoxicity. Among them, only the once-daily dosing of aminoglycosides has been brought to the clinic and physicians are now increasingly adopting this approach to reduce the toxicity of these agents. The incidence of aminoglycoside nephrotoxicity can be further reduced in view of the recent data on the circadian variations of their nephrotoxicity. In fact, it has been clearly demonstrated in both experimental animals and humans that the toxicity is maximal when the drug is injected during the rest period compared with the activity period. Thus, injecting aminoglycosides once-daily at the time of the lowest toxicity is actually the most interesting and clinically applicable approach to reduce aminoglycosides toxicity.
Beauchamp
D
D
Centre de Recherche en Infectiologie, and Université Laval, Ste-Foy, Quebec, Canada. denis.beauchamp@crchul.ulaval.ca
Labrecque
G
G
D000617:Aminoglycosides; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D002227:Carbazoles / Q000627:therapeutic use; D000077261:Carvedilol; D019454:Chronotherapy; D003404:Creatinine / Q000097:blood; D017576:Daptomycin / Q000627:therapeutic use; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008657:Metabolic Clearance Rate; D011412:Propanolamines / Q000627:therapeutic use; D051437:Renal Insufficiency / Q000139:chemically induced* / Q000517:prevention & control
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol; D003404:Creatinine; D017576:Daptomycin